Literature DB >> 32350558

Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease.

Min Seok Baek1, Hanna Cho1, Hye Sun Lee2, Jae Yong Choi3,4, Jae Hoon Lee3, Young Hoon Ryu5, Myung Sik Lee1, Chul Hyoung Lyoo6.   

Abstract

PURPOSE: To investigate the temporal trajectories of tau and amyloid-β (Aβ) accumulation in Alzheimer's disease (AD) by using the longitudinal positron emission tomography (PET) study.
METHODS: A total of 132 participants, who were healthy volunteers or recruited in our memory disorder clinic, completed longitudinal 18F-flortaucipir and 18F-florbetaben PET studies with a mean follow-up time of 2 years. Referencing baseline data from 57 Aβ-negative cognitively unimpaired individuals, Z-scores and their annual changes were calculated with the global cortical or regional standardized uptake value ratios measured at baseline and follow-up after correcting for partial volume effect. The temporal trajectories of tau and Aβ burden as a function of time were obtained based on the spline models from the annual changes and baseline Z-score data.
RESULTS: Tau burden first emerged in the Braak's stage I-II regions, followed by stage III-IV regions, and finally in the stage V-VI regions. Time intervals between two time points at which Z-score curves rose above 2 were 17.3 years for the stages I-II and III-IV and 15.2 years for the stages III-IV and V-VI. Rise in the tau curve for stages I-II preceded that for global cortical Aβ, while the rise in global cortical Aβ curve preceded that for global cortical tau. Aβ accumulation rate was attenuated during the surge in tau burden in the global cortex and reached a plateau.
CONCLUSION: Sequential appearance of Aβ and tau accumulation supports a hypothetical dynamic biomarker model and Braak's hierarchical tau spreading model in AD.

Entities:  

Keywords:  18F-flortaucipir; Alzheimer’s disease; Positron emission tomography; Tau

Mesh:

Substances:

Year:  2020        PMID: 32350558     DOI: 10.1007/s00259-020-04773-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  11 in total

Review 1.  Neuropathology of Alzheimer's Disease.

Authors:  Jorge A Trejo-Lopez; Anthony T Yachnis; Stefan Prokop
Journal:  Neurotherapeutics       Date:  2021-11-02       Impact factor: 6.088

2.  Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.

Authors:  Wha Jin Lee; Jesse A Brown; Hye Ryun Kim; Renaud La Joie; Hanna Cho; Chul Hyoung Lyoo; Gil D Rabinovici; Joon-Kyung Seong; William W Seeley
Journal:  Neuron       Date:  2022-04-19       Impact factor: 18.688

3.  Temporal trajectory of biofluid markers in Parkinson's disease.

Authors:  Min Seok Baek; Myung Jun Lee; Han-Kyeol Kim; Chul Hyoung Lyoo
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

Review 4.  The Toxicity and Polymorphism of β-Amyloid Oligomers.

Authors:  Ya-Ru Huang; Rui-Tian Liu
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

5.  Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.

Authors:  Alexis Moscoso; Michel J Grothe; Nicholas J Ashton; Thomas K Karikari; Juan Lantero Rodriguez; Anniina Snellman; Marc Suárez-Calvet; Henrik Zetterberg; Kaj Blennow; Michael Schöll
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

Review 6.  Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.

Authors:  E E Wolters; A Dodich; M Boccardi; J Corre; A Drzezga; O Hansson; A Nordberg; G B Frisoni; V Garibotto; R Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

7.  Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease.

Authors:  Myung Jun Lee; Kyoungjune Pak; Han-Kyeol Kim; Kelly N Nudelman; Jong Hun Kim; Yun Hak Kim; Junho Kang; Min Seok Baek; Chul Hyoung Lyoo
Journal:  NPJ Parkinsons Dis       Date:  2021-11-26

8.  Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid.

Authors:  Jun Pyo Kim; Min Young Chun; Soo-Jong Kim; Hyemin Jang; Hee Jin Kim; Jee Hyang Jeong; Duk L Na; Sang Won Seo
Journal:  Front Aging Neurosci       Date:  2022-02-07       Impact factor: 5.750

9.  The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.

Authors:  Hyung-Ji Kim; Jungsu S Oh; Jae-Sung Lim; Sunju Lee; Sungyang Jo; E-Nae Chung; Woo-Hyun Shim; Minyoung Oh; Jae Seung Kim; Jee Hoon Roh; Jae-Hong Lee
Journal:  Alzheimers Res Ther       Date:  2022-07-11       Impact factor: 8.823

Review 10.  Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Authors:  Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.